Happel David bought SGMT
February 19, 2026 · Form 4 insider transaction
Happel David bought 256,000 shares of Sagimet Biosciences Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.
Direction
Acquired (buy-side)
Shares
256,000
Price
$0.00
Total value
N/A
InsiderHappel David
RoleOfficer, Director
SecurityStock Option (Right to Buy)
Transaction codeA: Grant or award
Transaction dateFebruary 19, 2026
Filing dateFebruary 20, 2026
Shares owned after256,000
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.